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Abstract 
Health research and innovation (R&I) is attracting the attention of EU, national and regional poli-
cymakers. As Health policies are becoming a public policy priority – targeting not only social 
needs but also the overall economic development of EU countries – Health R&I have been identi-
fied as key areas of investment. However, despite the attempts to reduce inequalities also in this 
field, a strong concentration of Health R&I across EU regions still exists. The paper provides recent 
and novel empirical evidence on the topic, describing the concentration of Health patents, publica-
tions and EU project participation in top EU regions. Regional data help in assessing that, also in 
the Health sector, concentration is not only a cross-country but also a within-country issue. 
Keywords: EU regions, Research, Health. 
JEL classification: O33, R12. 
 
La concentrazione delle attività di innovazione e ricerca sanitaria 
nelle regioni UE 
 
Sommario 
La ricerca e innovazione (R&I) nel settore della salute sta attraendo sempre più l’attenzione dei poli-
cymaker nazionali, regionali ed europei, divenendo un’area strategica di investimento. Le politiche 
sulla salute sono infatti una priorità pubblica che ha come target non solo i bisogni sociali ma anche 
lo sviluppo economico nei paesi UE. Sebbene ci siano vari tentativi di ridurre le disuguaglianze 
all’interno della comunità europea, in questo settore esiste ancora una forte concentrazione in alcune 
aree rispetto ad altre. L’articolo fornisce nuove e recenti evidenze empiriche sull’argomento mo-
strando come la diversa distribuzione di attività brevettuali, pubblicazioni e partecipazione a progetti 
di ricerca non è solo divergente fra paesi ma anche fra regioni appartenenti ai singoli paesi UE. 
Parole chiave: regioni UE, Ricerca, Salute. 
Classificazione JEL: O33, R12. 
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Introduction 
 
Over the last years, European policymakers – both at the national and at 
the sub-national level – have widened their perspective regarding Health. 
From the generic attention to EU citizens’ healthcare, the focus has shifted 
towards a more complex framework where Health is an increasingly crucial 
social need. Already in 2007 with the white paper “Together for Health” 
(EC, 2007), the European Commission has identified the most crucial chal-
lenges regarding Health in its area: the increase in chronic diseases, the 
growing technological costs to face Health challenges and especially an 
ageing population. The consideration of those issues has then been included 
in the wider Europe 2020 Strategy (EC, 2013a), where two additional poli-
cy points have been highlighted: 
• Despite a generic increase in health conditions across EU countries, also 
an increase in inequality can be detected: «poorer and disadvantaged 
people die younger and suffer more often from disability and disease». 
• As a consequence, the concept of “investing in Health” has to be further 
developed. 
Indeed, such a shift in the analytical viewpoint, where Health policies 
should represent even more than in the past, a pivotal asset for the growth 
and cohesion of world society, can be found in other policy documents. As 
stated by the OECD (2014, p.9), «European countries have achieved signif-
icant gains in population health, but there remain large inequalities in 
health status both across and within countries». The efforts made by EU 
governments are reflected in several recent indicators: Health represents the 
second most important budget line in EU countries; overall the 73% of 
Health expenditures is funded by the public sector; and one employee out 
of 10 works in this sector. Therefore, especially in a EU society where life 
expectancy constantly grows, investing in Health has to be considered a 
compulsory task for achieving economic prosperity and social cohesion. 
Following this logic, Health is no more intended as a simple value in it-
self and it is becoming a public policy priority in the EU. For this reason, it 
is more and more important to focus on the economic aspects of Health. In-
vesting in the efficiency of Health system and especially on prevention will 
bring also increases in work productivity and will reduce social inequali-
ties. This is especially true when looking at poorer areas and performing an 
economic analysis at the sub-national level (Purohit, 2016). Furthermore, 
local public policies are to provide adequate Health services (Williams, 
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2017), which imply investments in Health Research and Innovation (R&I). 
Such goals are strictly related to the capability of R&I actors to make sub-
stantial advancements in the field (Intereconomics Forum, 2015). Not by 
chance, Health (together with Demographic change and Well-being) is one 
of the societal challenges of the EU Horizon 2020 research programme. 
Health goals are, therefore, intrinsically contained in the EU R&I strategy. 
Given the cumulative nature of R&I assets, however, EU countries and 
especially EU regions are expected to perform very differently. Even more 
than in general terms, the convergence of EU countries and regions in R&I 
has to be achieved with strong policy tools (Goecke & Hüther, 2016). Not 
by chance, then, the EU Horizon 2020 Programme addresses the inequali-
ties in the field of Health R&I, in order to find the right policy measures to 
reduce the gap among EU countries and regions. Such a gap might be par-
ticularly significant in the Health R&I domain, thus implying a minor ca-
pacity of some national and/or regional Health systems to respond ade-
quately to societal contextual needs. Following the approach mentioned 
above, less R&I in Health systems might lead to the worsening of the work 
and social conditions of some EU areas. 
The key role of Health is also confirmed by the fact that it is one of the 
most recurrent priorities for EU regions’ smart specialization strategies (S3, 
see Sörvik & Kleibrink, 2015). Indeed regions in almost all EU countries 
claim Health as their S3 priority. However, different regions might refer to 
specific – and very different – sub-areas of Health, targeting it from very 
different perspectives. That is, for instance, referring to Health when deal-
ing with the Pharmaceuticals, Biotech or Medical technology sectors, even-
tually key in their territory; or simply when dealing with their ageing popu-
lation; or maybe meaning the introduction in their systems of healthcare in-
novations, such as e-Health. 
To tackle such a challenging perspective, a deeper knowledge about the 
availability and quality of Health indicators across is needed. While the 
World Health Organisation (WHO) European regional office has developed 
an extensive exercise for developing adequate healthcare indicators (WHO, 
2012), measures of Health R&I in Europe are very scarce. We claim that 
such limited evidence is in contradiction with the idea of smarter invest-
ments in Health and might eventually bring to incorrect policy decisions in 
EU countries and regions. In particular, a poor knowledge about Health 
R&I performances and the use of inadequate indicators in Europe might 
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hide the real inequalities in the sector, thus extending instead of reducing 
the gap between top and least performing countries. 
This paper aims at better understanding Health R&I inequalities, includ-
ing their technological and economic dimensions, in Europe. It is structured 
as follows: in section 2 we report the main data limitations and the method-
ological problems in mapping Health R&I in the EU; in section 3, using 
novel data, we provide an overview of the current situation in EU Health 
R&I, showing the concentration and polarisation across countries and re-
gions; in section 4 we provide some conclusions and policy remarks. 
 
 
1. The (limited) mapping of Health R&I in the EU 
 
The difficulty in measuring Health R&I is intrinsically related to its def-
inition. Considering the most relevant measure – that is Health R&D – a 
warning comes from an OECD report related to R&D in Health (OECD, 
2001). It is there stated that «in the widest sense we are interested in all 
R&D which is relevant to human health. Here there are no generally ac-
cepted international definitions or guidelines on coverage. There are few 
(if any) areas of investigations which can “logically” be excluded from 
possible relevance to health – perhaps cosmology». To overcome such a 
problem, the WHO in 2013 organised an “Informal workshop on monitor-
ing financial flows in support of health research & development”. This 
workshop has reinforced, in particular, the idea of overcoming the limita-
tions of data availability for Health R&D. Following the WHO workshop, 
the newly-born Global Observatory for Health R&D by OECD and WHO 
has already started to work on better indicators for measuring Health 
R&D1. First results of the Observatory have led to estimations of Health 
R&D and clinical trials provided for all world countries in a recent Lancet 
 
 
 
1 The idea behind this Global Observatory is to monitor and analyze relevant infor-
mation on Health R&D, building on national and regional observatories (or equivalent func-
tions) and existing global data collection mechanisms with a view to contributing to the 
identification of gaps and opportunities for health R&D. 
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publication (Røttingen et al., 2013). Such estimations confirm the high de-
gree of concentration in the EU. As shown in figure 1, the highest shares of 
expenditure in Health R&D on GDP are detected for most technologically 
advanced EU countries, including Sweden, Denmark, UK and central EU 
countries such as Germany, Netherlands and Belgium. With the notable ex-
ception of Slovenia and partially Hungary, the least performing countries 
belong to Eastern Europe. However, according to the Observatory itself, a 
lot of work still remains to be done in order to provide stakeholders with 
the best information to monitor and assess Health R&I in all countries and 
regions. 
 
Fig. 1 – Health R&D (as a percentage of GDP) in EU countries 
 
 
Source: Own elaboration on Røttingen et al. (2013). Year: 2010 or latest available year. 
 
For mapping Health R&I, there are also other methodological problems. 
On the one side, this is related to the complexity and specificity of the sec-
tor: Health includes manufacturing (e.g. the pharmaceuticals) and services 
(e.g. the hospitals) activities; it includes very strong investment both by the 
public and by the private bodies; it relies on strong propriety protection for 
some technological aspects, while it implies the full accessibility of 
knowledge for others; it affects both the macro level (the society as a 
whole) and the micro level (companies, professionals, individual citizens). 
On the other side, then, there is a more practical problem related to the in-
stitutional level at which the policies decisions are taken: while Health pol-
icies often involve decisions at the NUTS2 regional level (e.g. using EU 
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Structural Funds, see EC, 2015), many indicators which should sustain the 
decision processes only exist at the country level. 
In fact, the joint analysis of R&I figures at the NUTS2 regional and sectorial 
(Health) level is not straightforward. Usually the deepening of one dimension 
(i.e. the regional one) excludes that of the other one (the sectorial). Indeed the 
most important publication on the innovativeness of EU regions (that is the Re-
gional Innovation Scoreboard) does not fully cover any specific sector. Region-
al/sectorial analyses are usually included in case studies or in reports covering 
one country only or other limited breakdowns (EC, 2013b). Providing ad ade-
quate map of Health R&I in all NUTS2 regions has been therefore one of the 
main point of a Horizon 2020 project, aimed at filling in the informative gap in 
terms of Health at the regional level, in the EU2. 
 
 
2. An overview of the concentration and disparities of Health 
R&I in Europe 
 
The mapping of Health R&I has been undertaken selecting the most com-
mon indicators in the economics of innovation (Smith, 2005): scientific 
publications and patent applications. Although it is arguable that both indi-
cators concern more research than innovation, also in the Health sector, it is 
clear that they catch two different aspects of the R&I process. It is in fact 
expected that publications reflect more the public sector involvement, while 
patents are closer to the private engagement in R&I (Callon, 1994). Alt-
hough this distinction has not to be intended as normative, regional data on 
Health patents and publications give a confirmation of it. In table 1 we 
show the correlation coefficients between regional Health outcomes (pa-
 
 
 
2  The project "European regions network for Health Research & Innovation", funded by the 
Horizon 2020, having as main goal to propose new initiatives and concrete approaches to EU, na-
tional and regional decision-makers in Health to: i) reduce the gaps in Health R&I across the EU 
regions, ii) to increase the participation in Horizon 2020, and iii) to facilitate synergies between 
Horizon 2020 (H2020) and European Structural & Investment Funds (ESIFs). 
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tents and publications) and the breakdown of the main innovation input 
variable, that is R&D expenditure. The breakdown allows to identify the 
share of R&D performed in each region by the three main sectors: business, 
government and higher education (BERD, GOVERD and HERD respec-
tively). In table 1 it is clearly shown as the business sector has a higher cor-
relation coefficient with patents, while the government sector with publica-
tions. Intermediate values come out for the higher education sector, and this 
reflects the specificity of universities for which both outcomes are relevant. 
 
Tab. 1 – Correlation between R&D inputs and outputs 
BERD (business expenditure in R&D), GOVERD (government expenditure in R&D) and HERD (high-
er educational R&D expenditure) refers to year 2011 because of better data quality with respect to pre-
vious years.  Correlations are significant at 1% level. 
 
In figures 2 and 3 we show the results of the mapping. The maps show a clear 
concentration of Health R&I in a limited number of countries and regions. 
Northern EU countries always show the highest performances, although the two 
maps do not perfectly coincide. Only four countries (Denmark, Ireland, the 
Netherlands and Sweden) rank at the top in both indicators, suggesting that spe-
cialisation in the sector might be more relevant than the size of the national 
economies. In fact, several large EU countries only rank in the second quartile, in 
either one indicator or both. As expected, the almost totality of least performing 
countries are Eastern EU ones, confirming their urgent need to fill in the gap 
with the rest of Europe. Not by chance, policy instruments3 at the EU level have 
 
 
 
3 The definition of Widening countries, which are currently devoted special attention 
and resources (e.g. a dedicated budget of the Horizon 2020 programme), can be found in 
EC, 2015, or at: https://ec.europa.eu/programmes/horizon2020/en/h2020-section/spreading-
excellence-and-widening-participation)  
R&D expenditure 
Health Patents 
(2008-2010) 
Health Publications 
(2008-2012) 
BERD R&D  0.7906* 0.6039* 
GOVERD R&D 0.6829* 0.7089* 
HERD 0.7488* 0.9074* 
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been recently adopted to tackle the issue and try to help catching-up countries in 
R&I. 
 
Fig. 2 – Health publications and patents in EU-28 countries, by population 
                
Scientific publications   EPO patent applications 
 
 
 
Source: Own elaboration on European Commission – DG Research data. Patents and pub-
lications have been classified by FP7 Health thematic priority. Year: average 2008-2012 for 
publication, average 2008-2010 for patents. Colours reflect the quartiles. 
 
Fig. 3 – Health publications and patents in EU-28 regions, by population 
                  
                   Scientific publications                  EPO patent applications 
 
 
 
 
Source: Own elaboration on European Commission – DG Research data. Patents and pub-
lications have been classified by FP7 Health thematic priority. Year: average 2008-2012 for 
publication, average 2008-2010 for patents. Colours reflect the quartiles. Grey colour refers 
to missing data. 
115 
 
 
 
However, what emerges by looking at regional maps is that concentra-
tion is not only a cross-countries matter. Indeed, in almost all countries 
there is a high polarisation of regions in terms of Health R&I outcomes. If 
we look at regional publications, we can observe that almost all countries 
have at least one top region, either belonging to the first quartile (mostly in 
the case of Western EU countries) or to the second one (especially for East-
ern EU ones). It is instead in the case of patent applications that the cross-
country and within-country polarisations tend to coincide: top regions are 
almost all located in Central Europe (including Germany, BENELUX but 
also parts of France and Northern Italy) and in Northern countries (Ireland, 
UK and Scandinavian ones). In other words, the regional patent map 
strongly reflects the industrialisation of EU countries and its already known 
concentration. While, concerning scientific publications, a more “democrat-
ic” spread of the indicator might suggest a positive role of public and high-
er education sectors engagement in Health R&I. 
The cross- and within-countries polarisation is then appearing also in the 
main indicators of the funding of Health R&I. Figure 4 shows the distribu-
tion of FP7 Health project participants (in the whole 2007-2013 period). 
Again, Western EU countries show both the highest average values but also 
a great disparity between their top and least performing regions. In the 
group of Widening countries mentioned above, only Slovenia and Czech 
Republic show performances in line with some of the non-Widening ones. 
 
Fig. 4 – Regional dispersion of FP7 Health projects participation, per million population: 
average, minimum and maximum values. 
 
Source: EC, CORDA. 
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Such a figure helps in better understanding the real extent of concentra-
tion in European Health R&I. In fact, couples of countries with a very simi-
lar average can have a completely different situation behind. We make 
some examples. A good performing country as the Netherlands has a higher 
average than Denmark; however, the top Danish region achieves a maxi-
mum score of more than 140 projects per million population, while the top 
Dutch one does not go beyond 120. Even more, the top region in Europe 
(London) belongs to a country (UK) whose average is not particularly high. 
Then, a low performing country in terms of average, that is the Czech Re-
public, shows a top region that is in line with countries with higher averag-
es (e.g. Slovenia and Ireland) and even above large countries (e.g. Italy). 
Of course, having a low average might signal the strong unbalances that 
exist in some EU countries. Indeed, many countries have just one or two 
spots of better performance, as compared to a very poor environment in the 
rest of their territories. The joint analysis of the national and the NUTS2 
regional level, then, is even more needed to depict the concentration and 
unbalances of Health R&I, in both top and least performing countries.  
The figures shown confirm the idea that less performing regions and 
countries might need to catch-up and reinforce their R&I performance. As 
already mentioned, in the Horizon 2020 there is a small share of the overall 
budget dedicated to Widening countries, including all Eastern countries 
plus Luxembourg and Portugal. The definition of Widening country fol-
lows the EC approach of measuring in a synthetic way the outcomes of the 
R&I process, as well as its excellence. Indeed the definition derives from 
the composite indicator of Research Excellence, put forward in a EC-JRC 
report (2013) which aims at measuring research excellence in Europe, at 
country level, from a multiple point of view. The (top) quality of scientific 
and technological outputs concerns four different typologies of research ac-
tivities: highly-cited publications; high-quality patent applications; quality 
of universities and research institutes; and capacity to receive prestigious 
grants such as the ERC ones. 
This indicator has not only an intrinsic motivation that is to quantify al-
together the different dimensions of research excellence. From a policy per-
spective, the indicator provides a synthetic overview of R&I to better un-
derstand which European countries are less performing and therefore in 
need of specific policy support. Not by chance, Widening countries are 
those below the 70% of the EU average. 
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In the framework of the RegHealth-RI project, an attempt has been 
made to replicate the EC-JRC indicator for the Health sector, with minor 
adaptations. Unfortunately, the regionalisation of this indicator – that we 
consider very important for policy support reasons – is not measurable for 
strong lack of data4. At the national level, the Health Research Excellence 
indicator has been calculated as shown in figure 5, where it is also com-
pared to the original EC-JRC one. 
 
Fig. 5 – Comparison of variables included in the composite indicators 
 Composite indicator research excellence (EC-JRC, 2013) 
(1) Top 10% 
most cited  
publications 
(2000-2007)  
(2) Top Universi-
ties & PROs per 
GERD (2003-
2007, 2004-2008) 
(3) PCT Pa-
tents per popu-
lation (2000-
2008) 
(4) ERC Grants per 
public R&D (2007-
2011) 
RegHealth-RI composite indicator research excellence 
(1) Health Top 
10% most cited 
publications  
(2008-2009) 
(2) Health TOP 
universities and 
PROs (2007-
2012)  
(3) Health PCT 
patents per 
population  
(2008-2010) 
(4) Health ERC Grants 
per public R&D 
(GERD+HERD) (up-
dated years) 
 
The intensity of the Health Research Excellence indicator is displayed, 
for all EU countries, in figure 6, where again the four colours represent the 
quartiles of the distribution. 
Although the composite indicator of Health research excellence at coun-
try level appears similar to the EC-JRC one, important differences emerge. 
For some top performing countries, the Health indicator inverts the overall 
ranking: Italy goes up from the second to the first quartile, while for Swe-
den the opposite happens. Overall, the predominance of Nordic and Cen-
tral-Western EU countries is confirmed. The last quartile includes only 
Eastern European countries. 
 
 
 
 
4 To make an example, the lack of information of most cited publications in Health 
available for all regions. Moreover, given the problematic issues identified also at the na-
tional level for some variables, the risk of calculating a regional indicator was to increase 
even more its unreliability. 
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Fig. 6 – RegHealth-RI project Composite Indicator of Health Research Excellence 
 
 
Source: Own elaboration on RegHealth-RI data 
 
All in all, we can observe that such a picture almost overlaps with those 
of figure 2. This is not surprising, as it merges similar information that we 
have presented there and similar to those in figure 4. In other words, we be-
lieve that such a composite indicator might hide two levels of differences: 
• The specific performance of single countries in one indicator (e.g. pub-
lications or patents or EU project participation); 
• The within-countries regional polarisation, as we have shown in figures 
3 and 4. 
In practical terms, it is suggested that for those widening regions with 
low levels of scientific outcomes (health publications) public policies 
should be aimed at developing local competences. A direct objective might 
be that of increasing the share of highly educated workers on total popula-
tion. Vice versa, those widening regions with good scientific performance 
but that show low performances in terms of health patents , it is suggested 
to introduce more policies aimed at the networking with partners from ad-
vanced regions with stronger innovation capabilities, possibly via public-
private partnerships. 
Therefore, from a policy perspective we suggest that a deeper and de-
tailed analyses of R&I variables can be more useful than a synthetic picture 
of the overall phenomenon. Detailed analyses can better inform national 
and regional policymakers about their specific (e.g. regional & sectorial) 
strengths and weaknesses, to adopt the most suitable policies. One of the 
aims of the Horizon 2020 project from which this paper originated was to 
provide a sectoral and regional breakdown of health R&I variables. The 
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first descriptive outcomes have been presented in this paper. At the mo-
ment, data do not allow further analyses, as most of variables are still avail-
able at the regional or at the sectoral level alternatively. To proceed with 
detailed analyses suggested here, it is recommended that additional evi-
dence, especially on the input side of health R&I, is gathered. The prelimi-
nary outcomes of this paper suggest that this analytical direction can be 
fruitful, as it allows to better target innovation policies. Not only distin-
guishing between top and least performing regions, but also differentiating 
different types of regions within these two categories. 
 
 
Conclusions 
 
In this paper, we have shown the degree of concentration of Health R&I 
in EU countries and regions. Being R&I more and more key in shaping EU 
Health policies, shifting from the pure measure of healthcare to a wider 
concept of “investing in Health”, we believe this mapping is of great value. 
This is particularly relevant for less performing countries (so called Widening) 
that have and deserve dedicated funding and resources. In fact, their R&I per-
formances are still very far from that of most advanced EU countries. 
However, we also suggest that such a Widening definition based on 
composite indicators (EC-JRC, 2013) might be misleading and a wider ana-
lytical approach should be followed. Being Health, on the one side, and 
R&I, on the other side, increasingly key issues for EU policy. 
In addition, given the growing relevance of policies at the regional level, 
also in the framework of Smart Specialisation Strategies, there is the need 
of improving measures of regional & sectorial Health R&I. In fact, these 
sub-national measures might catch specific Health activities and subsectors 
which singularly or jointly may contribute to the development of some re-
gions, better than standard classifications (e.g. NACE codes). Regional data 
remain also crucial to identify whether the polarisation of R&I outcomes 
happens even within countries, also the most developed ones. 
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Goecke, H. & Hüther, M. (2016). Regional Convergence in Europe, Intereconomics,  51(3), 
165–171. Doi:10.1007/s10272-016-0595-x 
Intereconomics Forum (2015). The impact of Horizon 2020 on Innovation in Europe. In-
tereconomics, Vol. 50, No. 1. 
OECD (2001). Measuring Expenditure on Health-related R&D. 
OECD (2014). Health at a Glance: Europe 2014. 
Purohit, B. C. (2016). Health care system efficiency: a sub-state level analysis for Orissa 
(India). Review of Urban & Regional Development Studies, 28(1), 55-74. Doi: 
10.1111/rurd.12044. 
Røttingen, J. A., Regmi, S., Eide, M., Young, A. J., Viergever, R. F., Årdal, C., Terry, R. F. 
(2013). Mapping of available health research and development data: what's there, what's 
missing, and what role is there for a global observatory?. The Lancet, 382(9900), 1286-
1307. Doi: 10.1016/S0140-6736(13)61046-6. 
Smith, K. (2005). Measuring Innovation. In  J. Fagerberg, D. C. Mowery, R. R. Nelson 
(Eds.), The Oxford Handbook of Innovation, Oxford, Oxford University Press. 
Sörvik, J. & Kleibrink A. (2015). Mapping innovation Priorities and Specialisation Patterns 
in Europe, S3 Working Paper Series, JRC Technical Reports – IPTS, No. 8, 2015. 
WHO (2012). The evidence base of Health 2020. 
Williams, G. (2017). Enhancing the value of health care services at regional level. Review 
of Urban & Regional Development Studies, 29(1), 46–62. doi:10.1111/rurd.12058. 
